Skip to content

Study · Systematic review · n = 103 · 2018

3 results

A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.

El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S

Neurosurgical review18 Aug 2016Cited by 17 (Europe PMC)

PMID27539610 (opens in a new tab)DOI10.1007/s10143-016-0775-y (opens in a new tab)PepBankPUB-27539610
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In traumatic brain injury patients, survival with Cerebrolysin did not differ from controls.

    In plain wordsIn brain injury patients, survival with Cerebrolysin did not differ from controls.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSurvival
    Study

    n = 103

    Comparator
    Controls
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    OR
    2.81
    survival
    95 % CI
    0.905 to 8.76
    survival

    Source sentences

    Summary
    Survival of cerebrolysin-treated patients did not differ from controls (103 patients; OR = 2.81; 95 % CI 0.905 to 8.76).
    2 context sentences
    Summary · context
    Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients.
    Summary · context
    Studies included patients in all age groups regardless of severity of trauma.
  2. 02HumanSystematic reviewEfficacy outcome

    In traumatic brain injury patients, Cerebrolysin increased the odds of favorable GOS versus controls.

    In plain wordsIn brain injury patients, Cerebrolysin increased the odds of favorable recovery scores compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFavorable Glasgow outcome score
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    OR
    3.019
    favorable GOS
    95 % CI
    1.76 to 5.16
    favorable GOS
    p
    0.003
    favorable GOS

    Source sentences

    Summary
    Patients treated with cerebrolysin (n = 112) had favorable GOS three times more than controls (OR 3.019; 95 % CI 1.76 to 5.16; p = 0.003*).
    2 context sentences
    Summary · context
    Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients.
    Summary · context
    Studies included patients in all age groups regardless of severity of trauma.
  3. 03HumanSystematic reviewEfficacy outcome

    In traumatic brain injury patients, Cerebrolysin increased the odds of cognition improvement versus controls.

    In plain wordsIn brain injury patients, Cerebrolysin increased the odds of cognitive improvement compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognition improvement
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    OR
    3.4
    cognition improvement
    95 % CI
    1.82 to 5.21
    cognition improvement
    p
    < 0.001
    cognition improvement

    Source sentences

    Summary
    The odds of cognition improvement in the treatment group was 3.4 times more than controls (OR 3.4; 95 % CI 1.82 to 5.21; p < 0.001*).
    2 context sentences
    Summary · context
    Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients.
    Summary · context
    Studies included patients in all age groups regardless of severity of trauma.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT06052787

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

Ain Shams Universityn = 1501 Sept 2023 to 1 Aug 2025

Traumatic Brain Injury

Trial pageClinicalTrials.govUpdated 19 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.